ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 571

Effect of Long-term Treatment with TNF-α Inhibitor on Lipid Profile in Spondyloarthritis: Data from Nationwide Korean College of Rheumatology Biologics (KOBIO) Registry

Jina Yeo1, Mi Ryoung Seo 1, Hee Jung Ryu 1, Hyo-Jin Choi 1 and Han Joo Baek 1, 1Division of Rheumatology / Department of Internal Medicine / Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: anti-TNF therapy, Biologic agents, Lipids, rheumatic disease and axial spondyloarthritis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 10, 2019

Session Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: In spondyloarthritis (SpA), the lipid profile changes due to the systemic inflammatory response. Theoretically, the proinflammatory state is associated with a decrease in total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG) than expected, and an increase in these lipid levels after anti-inflammatory therapies, such as tumour necrosis factor alpha (TNF-α) inhibitor. This study aimed to assess the influence of long-term treatment with TNF-α inhibitor on lipid profile and atherogenic index (AI) in patients with SpA.

Methods: Lipid data and AI of SpA patients treated with TNF-α inhibitor were analysed from the Korean College of Rheumatology Biologics (KOBIO) registry between 2012 and 2017. Patients exposed at least for one year to SpA approved dosage regimens of etanercept, infliximab, adalimumab or golimumab as first line treatment were included. The baseline lipid profile and AI were compared with between 0 – 12 months, 12 – 18 months, 18 – 24 months, > 24 months. AI was derived according to the logarithmic (TG/HDL-C).

Results: The records of 361 patients (male 279, female 82) were reviewed. Mean follow-up duration was 2.25 ± 0.03 year (0.24 – 5.66 years) and baseline Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was 6.0 ± 0.1. Treatment with TNF-α inhibitor was associated with increased levels of TC (173.66 ± 1.82 mg/dL at baseline, 191.93 ± 3.51 mg/dL; p = 0.001 at 0 – 12 months, and 188.88 ± 1.61 mg/dL; p < 0.001 at > 24 months), HDL-C (48.50 ± 0.80 mg/dL at baseline, 55.92 ± 2.83 mg/dL; p = 0.023 at 0 – 12 months, and 53.38 ± 0.88 mg/dL; p= 0.002 at > 24 months) and TG (118.14 ± 4.04 mg/dL at baseline, 157.05 ± 12.31 mg/dL; p = 0.029 at 18 – 24 months, and 159.90 ± 5.62 mg/dL; p < 0.001 at > 24 months), but no significant change in LDL-C. After treatment, AI increased from 0.77 ± 0.04 at baseline to 1.00 ± 0.04 (p < 0.001) at > 24months.

Conclusion: In patients with SpA, long-term treatment of TNF-α inhibitor was associated with increased TC, HDL-C, and TG levels and AI, whereas it presented no effect on LDL-C levels. Increased HDL-C may have beneficial effects, but evaluation of cardiovascular event rates during long-term treatment is needed to further characterize these findings and their possible clinical implications.


Disclosure: J. Yeo, None; M. Seo, None; H. Ryu, None; H. Choi, None; H. Baek, None.

To cite this abstract in AMA style:

Yeo J, Seo M, Ryu H, Choi H, Baek H. Effect of Long-term Treatment with TNF-α Inhibitor on Lipid Profile in Spondyloarthritis: Data from Nationwide Korean College of Rheumatology Biologics (KOBIO) Registry [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/effect-of-long-term-treatment-with-tnf-%ce%b1-inhibitor-on-lipid-profile-in-spondyloarthritis-data-from-nationwide-korean-college-of-rheumatology-biologics-kobio-registry/. Accessed February 26, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-long-term-treatment-with-tnf-%ce%b1-inhibitor-on-lipid-profile-in-spondyloarthritis-data-from-nationwide-korean-college-of-rheumatology-biologics-kobio-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.